Turn Therapeutics Inc. Common Stock TTRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.43K+213% | $34.93K-78.0% | $158.7K+153% | $62.68K+577% | $9.26K-5.2% | ||
| $1.14M-47.3% | $2.16M+23.0% | $1.75M+34.6% | $1.3M+247% | $375.74K+17.7% | ||
| $1.25M-43.2% | $2.19M+14.6% | $1.91M+40.0% | $1.37M+255% | $385K+17.0% | ||
| -$1.25M+43.2% | -$2.19M-14.6% | -$1.91M-40.0% | -$1.37M-255% | -$385K-17.0% | ||
| $275.17K-88.9% | $2.47M+26,286% | $9.37K-92.6% | $126.11K+123% | $56.45K+869% | ||
| -$970.97K— | —— | -$1.9M— | —— | -$328.55K-1.7% | ||
| -$0.03— | —— | -$0.07— | —— | -$0.01+50.0% | ||
| -$1.25M+43.2% | -$2.19M-14.6% | -$1.91M-40.0% | -$1.37M-255% | -$385K-17.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Turn Therapeutics Inc. Common Stock profitable?
- Turn Therapeutics Inc. Common Stock is not currently profitable: it reported a net loss of $3.5M over the trailing twelve months.
- What is Turn Therapeutics Inc. Common Stock's earnings per share?
- Turn Therapeutics Inc. Common Stock's diluted EPS over the trailing twelve months is $-0.13.
- Where does Turn Therapeutics Inc. Common Stock's income statement data come from?
- Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.